Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: Findings from a UK population-based patient cohort

BMJ Open

Volumn 4, Issue 1, 2014, Pages

  Smith, A G ^a   Painter, D ^a   Howell, D A ^a   Evans, P ^b   Smith, G ^b   Patmore, R ^c   Jack, A ^b   Roman, E ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; POPULATION; PROSPECTIVE STUDY; SEX DIFFERENCE; SOCIOECONOMICS; SURVIVAL RATE; SURVIVAL TIME; UNITED KINGDOM; AGE; ECONOMICS; EPIDEMIOLOGY; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; PROGNOSIS; SURVIVAL;

AGE FACTORS; ANTINEOPLASTIC AGENTS; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS;

EID: 84892896223     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004266     Document Type: Article

References (46)

1. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42.
2. Branford S. Monitoring after successful therapy for chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 2012;2012:105-10.
3. Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Cancer Netw 2012;10(Suppl 3):S1-13.
4. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 2012;87:1037-45.
5. Marin D. Management of the new patient with CML in chronic phase. Curr Hematol Malig Rep 2013;8:37-42.
6. Carella AM, Branford S, Deininger M, et al. What challenges remain in chronic myeloid leukemia research? Haematologica 2013;98:1168-72.
7. Zackova D, Klamova H, Dusek L, et al. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? Am J Hematol 2011;86:318-21.
8. Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009;23:602-4.
9. Pulte D, Gondos A, Redaniel MT, et al. Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist 2011;16:663-71.
10. Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008;22:1963-6.
11. Pulte D, Barnes B, Jansen L, et al. Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. J Hematol Oncol 2013;6:70. http://www.jhoonline.org/content/6/1/70 (accessed 16 Oct 2013).
12. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17. (Pubitemid 44903745)
13. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda. http//seer. cancer.gov/csr/1975- 2010/, based Novemb 2012 SEER data submission, posted to SEER web site, April 2013 2013.
14. Chen Y, Wang H, Kantarjian H, et al. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma 2013;54:1411-17.
15. Elting LS, Cooksley C, Bekele BN, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 2006;106:2452-8. (Pubitemid 43787670)
16. Niu X, Roche LM, Pawlish KS, et al. Cancer survival disparities by health insurance status. Cancer Med 2013;2:403-11.
17. Smith JK, Ng SC, Zhou Z, et al. Does increasing insurance improve outcomes for US cancer patients? J Surg Res 2013;185:15-20.
18. Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol 2009;89:14-23.
19. Accordino MK, Hershman DL. Disparities and challenges in adherence to oral antineoplastic agents. Am Soc Clin Oncol Educ Book 2013;2013:271-6.
20. Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011;86:471-4.
21. Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8.
22. Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-11.
23. Jain P, Kantarjian H, Cortes J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol 2013;14:127-43.
24. Smith A, Roman E, Howell D, et al. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 2010;148:739-53.
25. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer, 2008.
26. Office for National Statistics, 2001 Census: Aggregate data (England and Wales) [computer file]. UK Data Service Census Support. Downloaded from: http://casweb.mimas.ac.uk
27. Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011;105:1684-92.
28. Shack L, Jordan C, Thomson CS, et al. Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England. BMC Cancer 2008;8:271.
29. Department of Health. Reducing cancer inequality: evidence, progress and making it happen: a report by the National Cancer Equality Initiative, 2010. www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-114353
30. Government D for C and L. English indices of deprivation 2010-Publications-GOV.UK. 2011. https://www.gov.uk/government/publications/ english-indices-of-deprivation-2010
31. Cancer Research UK Cancer Survival Group. strel computer program and life tables for cancer survival analysis. 2006. http://www.lshtm.ac.uk/ncde/ cancersurvival/tools.htm
32. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
33. Gugliotta G, Castagnetti F, Palandri F, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011;117:5591-9.
34. Rousselot P, Cony-Makhoul P, Nicolini F, et al. Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study. Am J Hematol 2013;88:1-4.
35. UK CR. Non-Hodgkin lymphoma diagnosis and treatment statistics. Cancer Research UK. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/nhl/ treatment/diagnosis-and-treatment (accessed 26 Sep 2013).
36. Hoyle M, Rogers G, Moxham T, et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or-intolerant chronic phase chronic myeloid leukemia. Value Heal 2011;14:1057-67. http://www.sciencedirect.com/science/ article/pii/S109830151101549X (accessed 26 Sep 2013).
37. Natonal Institute for Health and Clinical Excellence. Myelofibrosis (splenomegaly, symptoms)-ruxolitinib: appraisal consultation document. NICE 2013. http://guidance.nice.org.uk/TA/Wave0/615/Consultation/DraftGuidance (accessed 26 Sep 2013).
38. Höglund M, Sandin F, Hellström K, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013;122:1284-92.
39. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 2009;22: 295-302.
40. Visser O, Trama A, Maynadié M, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012;48:3257-66.
41. Oliver S, Taylor F, Bolton E, et al. Haematological maligancies in England 2001-2008. 2012. http://www.ncin.org.uk/cancer-type-and-topic-specific- work/cancer-type-specific-work/haematological-cancers/
42. Natonal Institute for Health and Clinical Excellence. Leukaemia (chronic myeloid)-imatinib. 2003. http://guidance.nice.org.uk/TA70 (accessed 3 Oct 2013).
43. Natonal Institute for Health and Clinical Excellence. Leukaemia (chronic myeloid, first line)-dasatinib, nilotinib and standard-dose imatinib. 2012. http://guidance.nice.org.uk/TA251 (accessed 3 Oct 2013).
44. Natonal Institute for Health and Clinical Excellence. Leukaemia (chronic myeloid)-dasatinib, nilotinib, imatinib (intolerant, resistant). 2012. http://guidance.nice.org.uk/TA241 (accessed 3 Oct 2013).
45. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012;120:4684-91. http://bloodjournal. hematologylibrary.org/content/120/24/4684.short (accessed 2 Oct 2013).
46. Rezende VM, Rivellis A, Novaes MMY, et al. Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug Des Devel Ther 2013;7:699-710.